Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2-advanced breast cancer (PALOMA-1; TRIO-18)

被引：15

作者：

Finn, Richard S. ^{[1
]}

Crown, John P. ^{[2
]}

Lang, Istvan ^{[3
]}

Boer, Katalin ^{[4
]}

Bondarenko, Igor M. ^{[5
]}

Kulyk, Sergey O. ^{[6
]}

Ettl, Johannes ^{[7
]}

Patel, Ravindranath ^{[8
]}

Pinter, Tamas ^{[9
]}

Schmidt, Marcus ^{[10
]}

Shparyk, Yaroslav V. ^{[11
]}

Thummala, Anu R. ^{[12
]}

Voytko, Nataliya L. ^{[13
]}

Huang, Xin ^{[14
]}

Kim, Sindy T. ^{[14
]}

Randolph, Sophia S. ^{[14
]}

Slamon, Dennis J. ^{[1
]}

机构：

[1] Univ Calif Los Angeles, Los Angeles, CA USA

[2] Irish Cooperat Oncol Res Grp, Dublin, Ireland

[3] Orszagos Onkol Intezet, Budapest, Hungary

[4] Szent Margit Korhaz, Onkol, Budapest, Hungary

[5] Dnipropetrovsk City Multiple Discipline Clin Hosp, Dnepropetrovsk, Ukraine

[6] Donetsk City Oncol Dispensary, Donetsk, Ukraine

[7] Tech Univ Munich, Klinikum Rechts Isar, D-80290 Munich, Germany

[8] Comprehens Blood & Canc Ctr, Bakersfield, CA USA

[9] Petz Aladar Teaching Hosp Gyor, Gyor, Hungary

[10] Johannes Gutenberg Univ Mainz, Dept Obstet & Gynecol, D-55122 Mainz, Germany

[11] Lviv State Oncol Reg Treatment & Diagnost Ctr, Lvov, Ukraine

[12] Comprehens Canc Ctr Nevada, Henderson, NV USA

[13] Kyiv City Clin Oncol Ctr, Kiev, Ukraine

[14] Pfizer Oncol, San Diego, CA USA

来源：

关键词：

D O I：

10.1158/1538-7445.AM2014-CT101

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT101

引用

页数：2